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Only one case known to date, a 18-year-old female 
patient. 
Clinics 
Immature lymphoid blast population CD19+, CD10+, 
with no co-expression of myeloid markers. 
Treatment 
Treated with Imatinib; a complete remission (CR) was 
obtained. Continued CR after bone marrow 
transplantation (Follow-up: 15 months). 
Cytogenetics 
Cytogenetics morphological 
Normal karyotype. This translocation would be hard to 
detect using conventional cytogenetics. 
 
Figure 1: FISH analysis: (I) Interphase nuclei showing four FISH signals for ABL1 (orange) with a commercial BCR/ABL-DCDF probe. 
(II) Schematic diagram showing the position of the BAC clones corresponding to the 3' and 5' portions of the SHIP1 and ABL1 genes, 
with the color scheme used for the fluorescent labelling of the SHIP1/ABL1 DCDF probes. The BAC clones for SHIP1 were labelled with 
FITC and those for ABL1 were labelled with Texas Red. (SHIP1 clones: A: RP13-497I2 and B: RP13-916J2; ABL1 BAC clones: C: RP11-
57C19 and D: RP11-835J22). (III-V) Interphase FISH demonstrating the presence of three fusion signals using the SHIP1-ABL1-DCDF 
probes (III), two SHIP1-ABL1 fusion signals, when SHIP1-ABL1 fusion specific probes were used (IV) and presence of one reciprocal 
ABL1/SHIP1 fusion using the ABL1-SHIP1 fusion specific FISH probe (V) in the patient sample. With all three probe combinations one 
normal copy of each the SHIP1 and ABL1 locus was also confirmed. The probes used for the hybridization are indicated below each 
image. The fusion signals (yellow) are indicated by arrows. 
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Cytogenetics molecular 
ABL1 rearrangement observed in interphase cells but 
not on metaphase chromosomes by FISH using 
commercial BCR-ABL-DCDF probes (Abbott). FISH 
using SHIP-ABL-DCDF FISH probes showed two 
fusion signals indicating the SHIP1-ABL1 fusion and 
one fusion signal for the reciprocal fusion on interphase 
cells. The rearrangement was not observed on the 
metaphase chromosomes, possibly because the 
malignant cells did not go into mitosis. 





Other names: SHIP, SHIP1, SIP-145, hp51CN. 
DNA/RNA 
Transcript variant 1: NM_001017915.1; 26 exons, 4928 
bp mRNA.  
Transcript variant 2: NM_005541.3; 26 exons, 4925 bp 
mRNA.  
There is also an INPP5D transcript variant described 
with 29 exons in the Ensembl database (INPP5D-201 
ENST00000359570). 
Protein 
Proteins: Variant 1 contains 1189 aa and Variant 2  
contains 1188 aa.  
Domains: An N-terminal SH2 domain, an inositol 
phosphatase domain and two C-terminal protein 
interaction domains (Figure 3, upper box). 
Expression: The expression of SHIP1 is restricted to 
hematopoietic cells.  
Localization: Cytosol and plasma membrane; the 
localization of SHIP1 (cytosol vs. plasma membrane) is 
regulated by its SH2 domain which mediates 
interaction with tyrosine phosphorylated receptors.  
Function: SHIP1 is a phosphatase, which hydrolyzes 
the 5-phosphates from phosphatidylinositol (3,4,5)-
trisphosphate (Ptdins(3,4,5)P3; PIP3) and inositol-
1,3,4,5 tetrakisphosphate (Ins(1,3,4,5)P4; PIP4) 
(Damen et al., 1996), thereby negatively regulating he 
PI3K (phosphoinositide 3-kinase) pathway.  
The PI3K pathway is part of many important signallig 
pathways and regulates key cellular functions such as 
survival, proliferation, cell activation and cell migration 
(Krystal, 2000; Ward and Cantrell, 2001; Ward, 2006).  
SHIP1 regulates these important cellular functions by 
controlling PIP3 levels and Ras activity following 
cytokine stimulation (Batty et al., 1985; Damen et al.,
1996).  
Homology: Belongs to the inositol-1,4,5-trisphosphate 
5-phosphatase family.  





Figure 2: Partial sequence of the PCR product showing an in-frame fusion of SHIP1 with ABL1. 
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Figure 3: The upper two diagrams show the SHIP1 and the ABL1 proteins and the lower diagram depicts the SHIP1/ABL1 fusion protein. 
The arrows indicate the breakpoints in the individual proteins; numbers indicate amino acid positions. SH2: Src homology-2 domain; 
SH3: Src homology-3 domain; 5-ptase: Inositol 5-phosphatase domain; INPNY and ENPLY: Target sequences for the phospho tyrosine 
binding domains of other proteins; TK: Tyrosine kinase domain; DB: DNA binding domain; AD: Actin-binding domain. 
 




Only SHIP1-ABL1 fusion transcript was detected. The 
reciprocal ABL1-SHIP1 fusion transcript was not 
detected. 
Detection 
The SHIP1-ABL1 fusion transcript can be detected by 
5' SHIP1 forward primer (bp 997-1015): 5'-
TTGCTGCACGAGGGTCCTG-3' and 3' ABL1 
reverse primer (bp 1474-1454): 5'-
TCTCCAGACTGTTGACTGGCG-3' resulting in 477 
bp PCR product. 
Fusion protein 
Description 
The fusion protein leads to the constitutive activation of 
the ABL1 tyrosine kinase facilitated by the homo-di- 
and homo-heteromerization of the fusion protein via 
the dimerization domain within the N-terminal SHIP1 
portion contained in the fusion protein. 
Oncogenesis 
Constitutive activation of ABL1 tyrosine kinase 
activity and possibly inactivation of the putative tumor 
suppressor function of SHIP1. 
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